234 related articles for article (PubMed ID: 34476576)
1. Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status.
Corvigno S; Burks JK; Hu W; Zhong Y; Jennings NB; Fleming ND; Westin SN; Fellman B; Liu J; Sood AK
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3545-3555. PubMed ID: 34476576
[TBL] [Abstract][Full Text] [Related]
2. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
3. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
McAlpine JN; Porter H; Köbel M; Nelson BH; Prentice LM; Kalloger SE; Senz J; Milne K; Ding J; Shah SP; Huntsman DG; Gilks CB
Mod Pathol; 2012 May; 25(5):740-50. PubMed ID: 22282309
[TBL] [Abstract][Full Text] [Related]
5. Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer.
Launonen IM; Lyytikäinen N; Casado J; Anttila EA; Szabó A; Haltia UM; Jacobson CA; Lin JR; Maliga Z; Howitt BE; Strickland KC; Santagata S; Elias K; D'Andrea AD; Konstantinopoulos PA; Sorger PK; Färkkilä A
Nat Commun; 2022 Feb; 13(1):835. PubMed ID: 35149709
[TBL] [Abstract][Full Text] [Related]
6. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA
Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854
[TBL] [Abstract][Full Text] [Related]
7. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
[TBL] [Abstract][Full Text] [Related]
8. Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status.
Whitehair R; Peres LC; Mills AM
Int J Gynecol Pathol; 2020 Nov; 39(6):558-566. PubMed ID: 31851060
[TBL] [Abstract][Full Text] [Related]
9. Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.
D'Angelo E; Espinosa I; Felicioni L; Buttitta F; Prat J
Hum Pathol; 2023 Nov; 141():15-21. PubMed ID: 37673346
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
11. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
[TBL] [Abstract][Full Text] [Related]
12. Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
Tomao F; Musacchio L; Di Mauro F; Boccia SM; Di Donato V; Giancotti A; Perniola G; Palaia I; Muzii L; Benedetti Panici P
Gynecol Oncol; 2019 Jul; 154(1):138-143. PubMed ID: 31079832
[TBL] [Abstract][Full Text] [Related]
13. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.
; Goode EL; Block MS; Kalli KR; Vierkant RA; Chen W; Fogarty ZC; Gentry-Maharaj A; Tołoczko A; Hein A; Bouligny AL; Jensen A; Osorio A; Hartkopf A; Ryan A; Chudecka-Głaz A; Magliocco AM; Hartmann A; Jung AY; Gao B; Hernandez BY; Fridley BL; McCauley BM; Kennedy CJ; Wang C; Karpinskyj C; de Sousa CB; Tiezzi DG; Wachter DL; Herpel E; Taran FA; Modugno F; Nelson G; Lubiński J; Menkiszak J; Alsop J; Lester J; García-Donas J; Nation J; Hung J; Palacios J; Rothstein JH; Kelley JL; de Andrade JM; Robles-Díaz L; Intermaggio MP; Widschwendter M; Beckmann MW; Ruebner M; Jimenez-Linan M; Singh N; Oszurek O; Harnett PR; Rambau PF; Sinn P; Wagner P; Ghatage P; Sharma R; Edwards RP; Ness RB; Orsulic S; Brucker SY; Johnatty SE; Longacre TA; Ursula E; McGuire V; Sieh W; Natanzon Y; Li Z; Whittemore AS; Anna A; Staebler A; Karlan BY; Gilks B; Bowtell DD; Høgdall E; Candido dos Reis FJ; Steed H; Campbell IG; Gronwald J; Benítez J; Koziak JM; Chang-Claude J; Moysich KB; Kelemen LE; Cook LS; Goodman MT; García MJ; Fasching PA; Kommoss S; Deen S; Kjaer SK; Menon U; Brenton JD; Pharoah PDP; Chenevix-Trench G; Huntsman DG; Winham SJ; Köbel M; Ramus SJ
JAMA Oncol; 2017 Dec; 3(12):e173290. PubMed ID: 29049607
[TBL] [Abstract][Full Text] [Related]
14. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
[TBL] [Abstract][Full Text] [Related]
15. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
[TBL] [Abstract][Full Text] [Related]
16. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach.
Marchetti C; Minucci A; D'Indinosante M; Ergasti R; Arcieri M; Capoluongo ED; Pietragalla A; Caricato C; Scambia G; Fagotti A
Gynecol Oncol; 2020 Sep; 158(3):740-746. PubMed ID: 32553590
[TBL] [Abstract][Full Text] [Related]
18. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
[TBL] [Abstract][Full Text] [Related]
19. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer].
Liu WL; Wang ZZ; Zhao JZ; Hou YY; Wu XX; Li W; Dong B; Tong TT; Guo YJ
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):26-31. PubMed ID: 28190312
[No Abstract] [Full Text] [Related]
20. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study.
Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]